Biowaiver and PK linearity - EU [Study As­sess­ment]

posted by Susanh – Iceland, 2021-08-18 18:38 (473 d 21:34 ago) – Posting: # 22528
Views: 835

Dear all,
I´m involved in the development of an IR generic product for EU submission. There are 2 strengths of the reference product and the SmPC states that the exposure appears to be non-linear. But, I cannot find a dose study in the literature where both strengths are dosed in the same study. So, I did a 3-way pilot study with both strengths of the reference and 1 strength of the test product. ABE analysis on dose-adjusted AUCt of the reference was used to test dose proportionality. And the results showed that the upper CI is just outside the 80-125. On the other hand, if you compare the dose-adjusted means of the AUCt for the 2 strengths the difference is 8%.
The EU guideline for IR states: “Assessment of linearity will consider whether differences in dose-adjusted AUC meet a criterion of ± 25%.”
Can I use this data to argue that PK is linear and a biowaiver for the lower strengths should be accepted?
Any comments/suggestion is greatly appreciated.

Complete thread:

UA Flag
Activity
 Admin contact
22,428 posts in 4,694 threads, 1,598 registered users;
12 visitors (0 registered, 12 guests [including 6 identified bots]).
Forum time: 15:13 CET (Europe/Vienna)

Statistics is the art of never having to say you’re wrong.
Variance is what any two statisticians are at.    C.J. Bradfield

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5